Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Study acronym: KaiNETIC-2
StatusActive, Not Recruiting
PhasePhase 3
SponsorKailera
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Trial sites expanded: 167 → 173 locations
    • Enrollment target: estimated 1156 to confirmed 1270
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 3 of 33 entries
  2. Trial sites expanded: 163 → 167 locations
    • Trial sites expanded: 116 → 163 locations
    v21
  3. Study sites: 116 to 163v20
  4. Primary endpoint(s) modifiedv19 Show 6 more changesShow less
    • Enrollment reduced: 1700 → 1156 participants
    • Trial sites expanded: 58 → 116 locations
    • Interventions: KAI-9531 (Drug), Placebo (Drug) to Placebo (Drug), Ribupatide (Drug)
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints revised (33)
    • Study title revised
  5. Trial sites expanded: 52 → 58 locationsv18
  6. Trial sites expanded: 49 → 52 locationsv17
  7. Study sites: 48 to 49v16
  8. Study sites: 46 to 48v15
  9. Study sites: 44 to 46v14
  10. Trial sites expanded: 37 → 44 locationsv13
  11. Trial sites expanded: 30 → 36 locationsv12
  12. Study sites: 30 to 36v11
  13. Trial sites expanded: 27 → 30 locationsv10
  14. Trial sites expanded: 24 → 27 locationsv9
  15. Study sites: 21 to 24v8
  16. Study sites: 20 to 21v7
  17. Study sites: 16 to 20v6
  18. Study sites: 12 to 16v5
  19. Study sites: 7 to 12v4
  20. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 7
    • Start date changed from estimate of Dec 2025 to Jan 12, 2026
    v3
  21. Re-verified, no change to tracked fieldsv2
  22. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Kailera
7 trials monitored
See all monitored trials
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
Trial Details
NCT Number NCT07284901
Lead Sponsor Kailera
Conditions
(from sponsor)		 Obesity With Diabetes, Overweight With Diabetes
Related terms Diabetes Mellitus, Obesity, Overweight
Enrollment 1,270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov